Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Erin Larkins"'
Autor:
Patricia Keegan, Amy E. McKee, Lauretta Odogwu, Xiaoping Jiang, Eunice Y. Lee, Richard Pazdur, Gideon M. Blumenthal, Luckson Mathieu, Reena Philip, Karen Bijwaard, Norma Griffin, Lisa Rodriguez, Kirsten B. Goldberg, Erin Larkins
Publikováno v:
The Oncologist
This article summarizes the FDA review of the efficacy supplement supporting approval of dabrafenib and trametinib administered concurrently for BRAF V600E‐mutant non‐small cell lung cancer.
On June 22, 2017, the Food and Drug Administration
On June 22, 2017, the Food and Drug Administration
Autor:
Sriram Subramaniam, Chao Liu, Kirsten B. Goldberg, Kun He, Weishi Yuan, Hong Zhao, Richard Pazdur, Patricia Keegan, Rajeshwari Sridhara, Gideon M. Blumenthal, Jingyu Yu, Amy E. McKee, Erin Larkins
Publikováno v:
The Oncologist
This article summarizes the evidence for the impact of BRAF mutations on treatment outcome of anti‐EGFR monoclonal antibodies. Based on a review of literature, eight meta‐analyses were included in this study, which consistently show that patients
Autor:
Erik Bloomquist, Gideon M. Blumenthal, Missiratch Biable, Richard Pazdur, Barbara Scepura, Patricia Keegan, Paul G. Kluetz, Erin Larkins, Shenghui Tang
Publikováno v:
The Oncologist. 20:1320-1325
On December 12, 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinu
Autor:
Patricia Keegan, Martha Donoghue, Eunice Y. Lee, Kirsten B. Goldberg, Erin Larkins, Karen Bijwaard, Ingrid Fan, Mallorie H. Fiero, Lauretta Odogwu, Luckson Mathieu, Reena Philip, Richard Pazdur, Gideon M. Blumenthal, Amy E. McKee, Lisa Rodriguez
Publikováno v:
The Oncologist
This article reviews the benefit‐risk assessment of osimertinib that led to approval of osimertinib for the treatment of patients with metastatic EGFR T790M mutation‐positive non‐small cell lung cancer whose disease had progressed after EGFR ty